De Motu Cordis grows its IP portfolio to 28 patents, fortifying innovations in emergency medicine for anaphylaxis with their drug-device dry powder inhaler.
Recent News
De Motu Cordis CMO, Prof. John Fraser, awarded the Order of Australia for his contributions to medicine and critical care research.
On November 1, 2024, DMC received a formal letter of support from Food Allergy Research and Education (FARE), the largest nonprofit organisation in the U.S. committed to enhancing the quality of life and health for individuals with food allergies through innovative research, education, and advocacy.